Hematology encompasses clinical and laboratory aspects of adult and pediatric diseases, both malignant and non-malignant. Studies of novel therapeutic agents, including targeted therapies and immunotherapies, have made great strides in understanding the fundamental biology of hematological diseases and have led to an increasing number of targeted and personalized treatments.
Through our experience in novel molecularly targeted agents and rare diseases, OPIS provides its clients with a variety of solutions for hematology trials that are scalable for both small biotechnology companies and global pharmaceutical organizations.
More than 150 studies managed
Indications: acute lymphoblastic leukemia, acute/chronic myeloid leukemia, genomic alterations of anaplastic lymphoma kinase, anemias, aplastic anemia, B-cell lymphoma/follicular lymphoma, beta-thalassemia, chronic lymphocytic leukemia, chronic myeloproliferative diseases, diffuse large B-cell lymphoma, graft versus host disease, haemophilia B (factorIX), haemophilia A, hodgkin’s and non-hodgkin’s lymphoma, hypereosinophilic syndrom, idiopathic thrombocytopenic purpura, multiple myeloma, myelodisplastic syndrome, myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, pure red cell aplasia, thromboembolism, transfusional hemosiderorisis, Von Willebrand disease
Phases: I, Ib, II, IIa, IIb, III, IIIb, IV
Other details: interventional and non interventional studies in adult and children